Cargando…

Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model

Chronic liver disease may result in a sequential progression through fibrosis, cirrhosis and lead, eventually, to hepatocellular carcinoma (HCC). Hepatic stellate cells (HSC) seem to be responsible for the fibrogenic response through the activation of an autocrine loop involving the chemokine recept...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ochoa-Callejero, Laura, Pérez-Martínez, Laura, Rubio-Mediavilla, Susana, Oteo, José A., Martínez, Alfredo, Blanco, José R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541191/ https://www.ncbi.nlm.nih.gov/pubmed/23326556 http://dx.doi.org/10.1371/journal.pone.0053992

Ejemplares similares

Implications of maraviroc and/or rapamycin in a mouse model of fragility
por: Pérez-Martínez, Laura, et al.
Publicado: (2020)

Small molecules related to adrenomedullin reduce tumor burden in a mouse model of colitis-associated colon cancer
por: Ochoa-Callejero, Laura, et al.
Publicado: (2017)

Maraviroc – A CCR5 Antagonist for the Treatment of HIV-1 Infection
por: Van Der Ryst, Elna
Publicado: (2015)

The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1
por: López-Huertas, María Rosa, et al.
Publicado: (2017)

New approaches in the treatment of HIV/AIDS – focus on maraviroc and other CCR5 antagonists
por: Schlecht, Hans P, et al.
Publicado: (2008)

Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
por: Lorenzen, Thore
Publicado: (2010)

The CCR5 antagonist maraviroc exerts limited neuroprotection without improving neurofunctional outcome in experimental pneumococcal meningitis
por: Le, Ngoc Dung, et al.
Publicado: (2022)

Maraviroc Prevents HCC Development by Suppressing Macrophages and the Liver Progenitor Cell Response in a Murine Chronic Liver Disease Model
por: Passman, Adam M., et al.
Publicado: (2021)

Hippocampal CCR5/RANTES Elevations in a Rodent Model of Post-Traumatic Stress Disorder: Maraviroc (a CCR5 Antagonist) Increases Corticosterone Levels and Enhances Fear Memory Consolidation
por: Merino, José Joaquín, et al.
Publicado: (2020)

Response to Letter to the Editor From Abobaker and Darrat: “Circulating levels of Calcitonin Gene-Related Peptide Are Lower in COVID-19 Patients”
por: Ochoa-Callejero, Laura, et al.
Publicado: (2021)

A Topical Microbicide Gel Formulation of CCR5 Antagonist Maraviroc Prevents HIV-1 Vaginal Transmission in Humanized RAG-hu Mice
por: Neff, C. Preston, et al.
Publicado: (2011)

A CCR5 antagonist, maraviroc, alleviates neural circuit dysfunction and behavioral disorders induced by prenatal valproate exposure
por: Ishihara, Yasuhiro, et al.
Publicado: (2022)

Lack of adrenomedullin in mouse endothelial cells results in defective angiogenesis, enhanced vascular permeability, less metastasis, and more brain damage
por: Ochoa-Callejero, Laura, et al.
Publicado: (2016)

Author Correction: Lack of adrenomedullin in mouse endothelial cells results in defective angiogenesis, enhanced vascular permeability, less metastasis, and less brain damage
por: Ochoa-Callejero, Laura, et al.
Publicado: (2020)

CCR5 Antagonist Maraviroc Inhibits Acute Exacerbation of Lung Inflammation Triggered by Influenza Virus in Cigarette Smoke-Exposed Mice
por: Ferrero, Maximiliano Ruben, et al.
Publicado: (2021)

Circulating Levels of Calcitonin Gene-Related Peptide Are Lower in COVID-19 Patients
por: Ochoa-Callejero, Laura, et al.
Publicado: (2021)

In Vitro Downregulation of Matrix Metalloproteinase-9 in Rat Glial Cells by CCR5 Antagonist Maraviroc: Therapeutic Implication for HIV Brain Infection
por: Gramegna, Pasqua, et al.
Publicado: (2011)

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry
por: Roche, Michael, et al.
Publicado: (2011)

CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth
por: Casagrande, Naike, et al.
Publicado: (2019)

Prevention of Bone Loss in a Model of Postmenopausal Osteoporosis through Adrenomedullin Inhibition
por: Martínez-Herrero, Sonia, et al.
Publicado: (2016)

In classical Hodgkin lymphoma the combination of the CCR5 antagonist maraviroc with trabectedin synergizes, enhances DNA damage and decreases three-dimensional tumor-stroma heterospheroid viability
por: Casagrande, Naike, et al.
Publicado: (2021)

A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations
por: Roche, Michael, et al.
Publicado: (2013)

Macrocybin, a Natural Mushroom Triglyceride, Reduces Tumor Growth In Vitro and In Vivo through Caveolin-Mediated Interference with the Actin Cytoskeleton
por: Vilariño, Marcos, et al.
Publicado: (2020)

CCL5 Levels Predict Stroke Volume Growth in Acute Ischemic Stroke and Significantly Diminish in Hemorrhagic Stroke Patients
por: Julián-Villaverde, Francisco José, et al.
Publicado: (2022)

Stochastic Model of In-Vivo X4 Emergence during HIV Infection: Implications for the CCR5 Inhibitor Maraviroc
por: Savkovic, Borislav, et al.
Publicado: (2012)

Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1
por: Giaquinto, Carlo, et al.
Publicado: (2018)

A randomized controlled clinical trial on the impact of CCR5 blockade with maraviroc in early infection on T-cell dynamics
por: Karris, Maile Y., et al.
Publicado: (2016)

Adrenomedullin as a Growth and Cell Fate Regulatory Factor for Adult Neural Stem Cells
por: Martínez-Herrero, Sonia, et al.
Publicado: (2012)

Adrenomedullin and tumour microenvironment
por: Larráyoz, Ignacio M, et al.
Publicado: (2014)

Adrenomedullin Is a Diagnostic and Prognostic Biomarker for Acute Intracerebral Hemorrhage
por: Julián-Villaverde, Francisco J., et al.
Publicado: (2021)

Improvement of endothelial function after switching previously treated HIV-infected patients to an NRTI-sparing bitherapy with maraviroc
por: Bernal, Enrique, et al.
Publicado: (2014)

A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity
por: Garcia-Perez, Javier, et al.
Publicado: (2015)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

Temporal profiles of blood pressure, circulating nitric oxide, and adrenomedullin as predictors of clinical outcome in acute ischemic stroke patients
por: SERRANO-PONZ, MARTA, et al.
Publicado: (2016)

Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals
por: Kawana-Tachikawa, Ai, et al.
Publicado: (2014)

Blocking the CCL5–CCR5 Axis Using Maraviroc Promotes M1 Polarization of Macrophages Cocultured with Irradiated Hepatoma Cells
por: Zhuang, Yuan, et al.
Publicado: (2021)

Dopamine Levels Induced by Substance Abuse Alter Efficacy of Maraviroc and Expression of CCR5 Conformations on Myeloid Cells: Implications for NeuroHIV
por: Matt, Stephanie M., et al.
Publicado: (2021)

The effects of Maraviroc on liver fibrosis in HIV/HCV co-infected patients
por: Ortega Gonzalez, Enrique, et al.
Publicado: (2014)

Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound
por: López-Huertas, María Rosa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cvsljsb1e4kafnbsrqh6gdu51c